Immunological response to highly active antiretroviral therapy in children with clinically stable HIV-1 infection.
We studied changes in 60 immunological parameters after the administration of highly active antiretroviral therapy (HAART) in 192 clinically stable antiretroviral drug-experienced HIV-1-infected children 4 months-17 years old. The studied immunological parameters included standard lymphocyte subsets and lymphocyte surface markers of maturation and activation. The most significant changes during the 48-week study period were seen for CD8(+), CD8(+)CD62L(+)CD45RA(+), CD8(+)CD38(+)HLA-DR(+), and CD4(+) T cell percentages (P < .0001 for all parameters). These changes suggest that significant decreases in the expression of activation markers and increases in the expression of naive markers in the CD8(+) T cell population may be related to better virologic control in these HIV-1-infected children, who had relatively stable immune function at the initiation of HAART. At week 44 of HAART, the major immunological parameters in these HIV-1-infected children moved from baseline values to about halfway to two-thirds of the way toward the values in healthy, uninfected children.
Rosenblatt
Howard M
HM
Allergy and Immunology Section, Texas Children's Hospital, Houston 77030, USA. hmrosenb@TexasChildrensHospital.org
Stanley
Kenneth E
KE
Song
Lin Y
LY
Johnson
George M
GM
Wiznia
Andrew A
AA
Nachman
Sharon A
SA
Krogstad
Paul A
PA
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology*; D015703:Antigens, CD / Q000097:blood; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002648:Child; D005434:Flow Cytometry; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology*; D006684:HLA-DR Antigens / Q000097:blood; D006801:Humans; D008213:Lymphocyte Activation; D018655:Lymphocyte Count; D013601:T-Lymphocytes / Q000276:immunology; D019562:Viral Load
D015703:Antigens, CD; D006684:HLA-DR Antigens